These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18953434)

  • 1. Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer.
    Gorringe KL; Choong DY; Williams LH; Ramakrishna M; Sridhar A; Qiu W; Bearfoot JL; Campbell IG
    Neoplasia; 2008 Nov; 10(11):1253-8. PubMed ID: 18953434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer.
    Wu X; Zhu Z; Li W; Fu X; Su D; Fu L; Zhang Z; Luo A; Sun X; Fu L; Dong JT
    Breast Cancer Res; 2012 May; 14(3):R73. PubMed ID: 22569290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHD5 is down-regulated through promoter hypermethylation in gastric cancer.
    Wang X; Lau KK; So LK; Lam YW
    J Biomed Sci; 2009 Oct; 16(1):95. PubMed ID: 19840376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas.
    Fujita T; Igarashi J; Okawa ER; Gotoh T; Manne J; Kolla V; Kim J; Zhao H; Pawel BR; London WB; Maris JM; White PS; Brodeur GM
    J Natl Cancer Inst; 2008 Jul; 100(13):940-9. PubMed ID: 18577749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing of CHD5 gene by promoter methylation in leukemia.
    Zhao R; Meng F; Wang N; Ma W; Yan Q
    PLoS One; 2014; 9(1):e85172. PubMed ID: 24454811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation.
    Du Z; Li L; Huang X; Jin J; Huang S; Zhang Q; Tao Q
    Oncotarget; 2016 Apr; 7(16):21618-30. PubMed ID: 26943038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer.
    Mulero-Navarro S; Esteller M
    Epigenetics; 2008; 3(4):210-5. PubMed ID: 18698156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic silencing of CHD5, a novel tumor-suppressor gene, occurs in early colorectal cancer stages.
    Fatemi M; Paul TA; Brodeur GM; Shokrani B; Brim H; Ashktorab H
    Cancer; 2014 Jan; 120(2):172-80. PubMed ID: 24243398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CHD5 Downregulation Associated with Poor Prognosis in Epithelial Ovarian Cancer.
    Wong RR; Chan LK; Tsang TP; Lee CW; Cheung TH; Yim SF; Siu NS; Lee SN; Yu MY; Chim SS; Wong YF; Chung TK
    Gynecol Obstet Invest; 2011; 72(3):203-7. PubMed ID: 21860208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHD5 a tumour suppressor is epigenetically silenced in hepatocellular carcinoma.
    Zhao R; Wang N; Huang H; Ma W; Yan Q
    Liver Int; 2014 Jul; 34(6):e151-60. PubMed ID: 24529164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The involvement of CHD5 hypermethylation in laryngeal squamous cell carcinoma.
    Wang J; Chen H; Fu S; Xu ZM; Sun KL; Fu WN
    Oral Oncol; 2011 Jul; 47(7):601-8. PubMed ID: 21636313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of CHD5 in human cancers: 10 years later.
    Kolla V; Zhuang T; Higashi M; Naraparaju K; Brodeur GM
    Cancer Res; 2014 Feb; 74(3):652-8. PubMed ID: 24419087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHD5, a tumor suppressor that is epigenetically silenced in lung cancer.
    Zhao R; Yan Q; Lv J; Huang H; Zheng W; Zhang B; Ma W
    Lung Cancer; 2012 Jun; 76(3):324-31. PubMed ID: 22186629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
    Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
    Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mRNA expression and epigenetic-based role of chromodomain helicase DNA-binding 5 in hepatocellular carcinoma.
    Heidari Z; Asemi-Rad A; Moudi B; Mahmoudzadeh-Sagheb H
    J Int Med Res; 2022 Jul; 50(7):3000605221105344. PubMed ID: 35808817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of CHD5 Inactivation in neuroblastomas.
    Koyama H; Zhuang T; Light JE; Kolla V; Higashi M; McGrady PW; London WB; Brodeur GM
    Clin Cancer Res; 2012 Mar; 18(6):1588-97. PubMed ID: 22294723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
    Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
    Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene methylation in gastric cancer.
    Qu Y; Dang S; Hou P
    Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CHD5 is a potential tumor suppressor in non small cell lung cancer (NSCLC).
    Baykara O; Tansarikaya M; Bulut P; Demirkaya A; Buyru N
    Gene; 2017 Jun; 618():65-68. PubMed ID: 28400267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
    Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
    Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.